

April 20, 2006
Nippon Kayaku Co., Ltd.
Shionogi & Co., Ltd.

Manufacturing and Marketing Approval for Premature Ovulation Inhibitor Cetrotide® (Cetrorelix Acetate) Obtained

Tokyo, April 20, 2006— Nippon Kayaku Co., Ltd. (Head Office: Tokyo, President: Koichiro Shimada) announced today that it has obtained manufacturing and marketing approval for Cetrotide® (cetrorelix acetate for injection, 3mg and 0.25mg) after having demonstrated the drug's efficacy and effectiveness in preventing premature ovulation during controlled ovarian stimulation.

Canadian biopharmaceutical company Æterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), through its fully-owned German subsidiary, Zentaris GmbH, is the worldwide licensor of rights to Cetrotide®, which has been approved for prevention of premature ovulation and sold in 92 countries including Europe and the United States.

In Japan, Nippon Kayaku and Shionogi & Co., Ltd. (Head Office: Osaka, President: Motozo Shiono) have been conducting co-development. Hereafter Nippon Kayaku and Shionogi are scheduled to make an agreement that Nippon Kayaku will import from Zentaris and manufacture Cetrotide® and Shionogi will market it and both companies will make preparations for the launch.

Nippon Kayaku and Shionogi will keep cooperative relationship in a highly specialized and knowledge-specific fertility treatment field to contribute very much to fertility treatment market in Japan.

Sales of Cetrotide® are scheduled to begin in Japan from September 2006.

#